223 patents currently held
83 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
5 more records may belong here and await a decision; they are not counted.
The next term ends in Oct 2027. from the record
Of the 83 now held by other companies, 39 name Université Paris Cité as their current owner, and 44 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
3
Ending by 2030
Oct 2027
Next term end
196
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 18, 2026 · includes USPTO assignment data published Nov 17, 2026, status data published Nov 18, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Nov 2039 · High confidence
Also notable
Ends May 2032 · High confidence
Also notable
Ends Feb 2036 · High confidence
Organ Perfusion Device
US 11,576,371
Cited by 19 later US patents, top 5% of utility patents granted in 2023 in our data. Protection runs to 2039.
Use of Low Dose IL-2 for Treating Autoimmune Related or Inflammatory Disorders
US 10,293,028
Cited by 36 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2032.
Prevention And/Or Treatment of Hearing Loss or Impairment
US 10,751,385
Cited by 15 later US patents, top 25% of utility patents granted in 2020 in our data. Protection runs to 2036.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Nov 21 to 23, 2026 · next Nov 21
- 5 fees due Dec 6 to 27, 2026 · next Dec 6
- 5 fees due Jan 14 to 25, 2027 · next Jan 14
- 8 fees due Feb 1 to 28, 2027 · next Feb 1
- 4 fees due Apr 1 to 30, 2027 · next Apr 1
- 4 fees due May 5 to 21, 2027 · next May 5
- 5 fees due Jun 10 to 30, 2027 · next Jun 10
- 6 fees due Jul 2 to 16, 2027 · next Jul 2
- 3 fees due Aug 11 to 20, 2027 · next Aug 11
- 4 fees due Sep 1 to 24, 2027 · next Sep 1
- 3 fees due Oct 9 to 16, 2027 · next Oct 9
Recent changes
- 11 of the patents on this record were granted since Aug 20, 2026
- 5 terms have ended since Aug 20, 2026
What they patent
The 5 largest of its 196 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
| Method for Stimulating T Lymphocytes with IL-2 | 5 in force | to Jun 2032 |
| Acoustic-Optical Imaging Methods and Systems | 4 in force | to Oct 2043 |
| Control Method for the Treatment of Brain Tissue Using an Ultrasonic Probe and an Implanted Acoustic Window on the Cranium | 3 in force | to Mar 2041 |
| Organ Perfusion Device | 3 in force | to Nov 2039 |
| Medical System | 3 in force | to Oct 2039 |
Patents held now
Soonest term end first.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,932,422 | Use of Chlorine Guanabenz Derivatives for Treating Polyglutamine Expansion Associated Diseases In force · High confidence | In force | High confidence | |
| US 7,897,044 | Fluid Separation Device In force · High confidence | In force | High confidence | |
| US 10,465,191 | Tricyclo-DNA Antisense Oligonucleotides, Compositions, and Methods for the Treatment of Disease held by Institut National de la Sante et de la Recherche Medicale, Association Institut de Myologie, Centre National de la Recherche Scientifique and Sorbonne Universite In force · High confidence | In force | High confidence | |
| US 9,080,170 | Modified U7 Snrnas for Treatment of Neuromuscular Diseases held by Sorbonne Université In force · High confidence | In force | High confidence | |
| US 8,961,499 | Surgical Instrument held by Sorbonne Université In force · High confidence | In force | High confidence | |
| US 9,662,357 | Novel Bacterium and Extracts of Said Bacterium and the Use of Same in Dermatology In force · High confidence | In force | High confidence | |
| US 9,084,811 | Novel Bacterium and Extracts of Said Bacterium and the Use of Same in Dermatology In force · High confidence | In force | High confidence | |
| US 10,765,723 | Use of Low Dose IL-2 for Treating Autoimmune - Related or Inflammatory Disorders held by Sorbone Universite In force · High confidence | In force | High confidence | |
| US 11,559,566 | Use of Low Dose IL-2 for Treating Autoimmune-Related or Inflammatory held by Sorbonne Université In force · High confidence | In force | High confidence | |
| US 12,491,232 | Low Dose IL-2 for Treating Autoimmune-Related or Inflammatory Disorders In force · High confidence | In force | High confidence |
Also on record, not counted in the 223: 83 patents in force now held by others · 42 patents ended · 265 applications pending · 126 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.